Given that proteins made recombinantly in bacteria are now commonly approved by the FDA as therapeutics [72], it should also now be within reach to include SP-B produced this way in novel therapeutics for common and frequently fatal conditions such as ARDS [39,40] or for drug delivery [41–43]. The gene discussed is SFTPB; the disease is acute respiratory distress syndrome.